Stunning Biomarkers Hint At Alzheimer’s—Years Early

Gloved hand holding a multiwell plate as a pipette dispenses liquid
Photo: Catalin Rusnac / Shutterstock

People whose bodies are “aging” faster than their birth certificate says now face up to 60% higher odds of developing vascular dementia, according to new biomarker research.

Story Snapshot

  • Several biological age tests, built from blood and DNA markers, predict future dementia even after accounting for actual age.
  • A five-year gap between biological and chronological age links to a 40% higher risk of vascular dementia or stroke, Swedish researchers found.
  • Not every aging clock works the same way, and one major test failed to predict decline in older women.
  • Chronological age and family genetics still matter, and no biological age test has been approved for clinical dementia screening.

New Blood And DNA Tests Track Aging Speed

Scientists now measure “biological age” using blood chemistry and DNA markers, not just birthdays. Large population studies show these tools, including tests called KDMAge, PhenoAge, and HDAge, predict future dementia risk. One study found people with faster biological aging faced 20% to 28% higher odds of developing dementia, even after researchers accounted for their actual age.

Researchers at Sweden’s Karolinska Institute found the gap matters a lot. People whose biological age ran five years ahead of their real age had a 40% higher risk of vascular dementia or stroke, according to lead researcher Jonathan Mak. A separate report found 16% of study participants had biological ages more than one year-standard-deviation older than expected, raising their overall dementia risk by 20% and their vascular dementia risk by 60%.

Blood Markers May Flag Risk Years Before Diagnosis

A 2025 study found that biological age acceleration lines up with blood markers tied to Alzheimer’s disease, including amyloid and tau proteins. Researchers say these blood-based age measurements can flag dementia risk up to three years before a doctor makes a diagnosis. A separate 11-year study found each one-year jump in biological age raised dementia risk by 7%, even after adjusting for the APOE gene and gender.

Women may face unique risks tied to aging speed. Research on older women in the Women’s Health Initiative Memory Study found one aging clock, called AgeAccelGrim2, predicted mild cognitive impairment and dementia independent of chronological age. Scientists also note that women carrying the APOE ε4 gene variant show faster cognitive decline than men with the same gene, suggesting biological age may capture risks that a birth certificate cannot.

Not Every Aging Clock Agrees, And Age Still Rules

The science has real gaps. In that same Women’s Health Initiative study, a different clock called AgeAccelPheno showed no meaningful link to dementia risk in women, proving these tools do not all work the same way. Researchers have not yet run large studies comparing how well biological age predicts dementia in women versus men, leaving that specific claim unproven.

Chronological age remains the strongest known predictor of dementia. One long-running study found that when researchers weighed every risk factor together, including brain scans and genetics, plain old age still came out on top. Alzheimer’s risk roughly doubles every five years after age 60, reaching one in three people by age 85, according to brain health expert Dr. Helena Popovic.

Biological age tests also correlate strongly with heart health and lifestyle habits. Cutting cholesterol, staying active, and quitting smoking all slow the aging clock, according to reporting on the research. That overlap raises a fair question: is biological age truly an independent warning sign, or mostly a stand-in for known heart and metabolic risks doctors already track?

No government agency has approved a biological age test for dementia screening, and federal research dollars still flow mostly toward drug development rather than biomarker validation. For families watching a parent’s memory slip, or worried about their own risk, that gap between promising science and real-world tools remains the central frustration. The data is real. The clinical payoff, for now, is not.

Sources:

docs.google.com, insideprecisionmedicine.com, pubmed.ncbi.nlm.nih.gov, pmc.ncbi.nlm.nih.gov, nature.com, medicalnewstoday.com, news.ki.se